Changes in plasma hormones and heart rate variability in patients receiving the cardiotoxic anti-cancer agent bevacizumab
Journal Articles
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
status
publication date
- September 2016
has subject area
- 1102 Cardiorespiratory Medicine and Haematology (FoR)
- 1117 Public Health and Health Services (FoR)
- Aged (MeSH)
- Aldosterone (MeSH)
- Angiogenesis Inhibitors (MeSH)
- Antineoplastic Agents (MeSH)
- Bevacizumab (MeSH)
- Cardiotoxins (MeSH)
- Cardiovascular System & Hematology (Science Metrix)
- Colorectal Neoplasms (MeSH)
- Female (MeSH)
- Follow-Up Studies (MeSH)
- Heart Rate (MeSH)
- Hormones (MeSH)
- Humans (MeSH)
- Male (MeSH)
- Middle Aged (MeSH)